JP2025514336A5 - - Google Patents

Info

Publication number
JP2025514336A5
JP2025514336A5 JP2024563656A JP2024563656A JP2025514336A5 JP 2025514336 A5 JP2025514336 A5 JP 2025514336A5 JP 2024563656 A JP2024563656 A JP 2024563656A JP 2024563656 A JP2024563656 A JP 2024563656A JP 2025514336 A5 JP2025514336 A5 JP 2025514336A5
Authority
JP
Japan
Prior art keywords
group
compound
substituted
cyano
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024563656A
Other languages
English (en)
Japanese (ja)
Other versions
JP7792730B2 (ja
JP2025514336A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/091140 external-priority patent/WO2023208108A1/zh
Publication of JP2025514336A publication Critical patent/JP2025514336A/ja
Publication of JP2025514336A5 publication Critical patent/JP2025514336A5/ja
Application granted granted Critical
Publication of JP7792730B2 publication Critical patent/JP7792730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024563656A 2022-04-27 2023-04-27 尿酸を降下させるために使用できる化合物 Active JP7792730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210456939 2022-04-27
CN202210456939.3 2022-04-27
PCT/CN2023/091140 WO2023208108A1 (zh) 2022-04-27 2023-04-27 可用于降尿酸的化合物

Publications (3)

Publication Number Publication Date
JP2025514336A JP2025514336A (ja) 2025-05-02
JP2025514336A5 true JP2025514336A5 (enExample) 2025-10-08
JP7792730B2 JP7792730B2 (ja) 2025-12-26

Family

ID=87872273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563656A Active JP7792730B2 (ja) 2022-04-27 2023-04-27 尿酸を降下させるために使用できる化合物

Country Status (6)

Country Link
US (1) US20250282753A1 (enExample)
EP (1) EP4516781A4 (enExample)
JP (1) JP7792730B2 (enExample)
CN (1) CN116715633B (enExample)
TW (1) TWI870839B (enExample)
WO (1) WO2023208108A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
MX2008001778A (es) * 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JPWO2010044403A1 (ja) * 2008-10-15 2012-03-15 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
WO2010044404A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 縮合複素環誘導体及びその医薬用途
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
JP5990106B2 (ja) * 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
KR20150138212A (ko) * 2013-03-29 2015-12-09 데이진 화-마 가부시키가이샤 피라졸 유도체
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
KR20170105021A (ko) * 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
JP6873904B2 (ja) * 2015-08-28 2021-05-19 Ils株式会社 キサンチンオキシダーゼ阻害剤
HUE052608T2 (hu) * 2015-09-02 2021-05-28 Sunshine Lake Pharma Co Ltd Karboxi-szubsztituált (hetero) aromás gyûrûs származékok, elõállítási eljárásaik és alkalmazásaik
EA037280B1 (ru) * 2015-09-10 2021-03-03 Цзянсу Атом Байосайенс Энд Фармасьютикал Ко., Лтд. Группа соединений, применяющихся для лечения или предупреждения гиперурикемии или подагры
CN107759588B (zh) * 2016-08-19 2020-10-23 江苏新元素医药科技有限公司 一类苯基-(吡唑并[1,5-a]吡啶-3-基)甲酮衍生物
BR112021001709A2 (pt) * 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
CN116438175B (zh) * 2020-11-11 2025-07-22 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用
WO2022233264A1 (zh) * 2021-05-07 2022-11-10 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Similar Documents

Publication Publication Date Title
MD3788045T2 (ro) Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
KR20220152293A (ko) Covid-19 관련 병태의 치료 방법
KR20120123659A (ko) 트리아졸로［4,5-ｄ］피리미딘 혈소판 응집 억제제의 공결정
JP7713253B2 (ja) キサンチンオキシダーゼ抑制剤
WO2019075086A1 (en) TREATMENT OF FOCAL SEGMENTAL GLOBEROSCLEROSIS WITH CCR2 ANTAGONISTS
ES3059451T3 (en) Compound used as ret kinase inhibitor and application thereof
CN119790055A (zh) 吡唑并嘧啶化合物及其医药用途
JP2021530525A (ja) ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
CN120731207A (zh) 6-烷氧基吡唑并嘧啶化合物及其药学用途
WO2016000568A1 (zh) 一种治疗痛风的化合物
JP2022549496A (ja) Ｃｒｆ受容体アンタゴニストおよび使用方法
JP7792730B2 (ja) 尿酸を降下させるために使用できる化合物
JP2008519049A (ja) 増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬
CN115974855B (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
CN101659659B (zh) 嘧啶衍生物及其医药用途
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
JP2022517984A (ja) 環内チアミジノアミド－アリールアミド系化合物及びｂ型肝炎を治療するためのその使用
CN116836154B (zh) 可用于痛风的化合物
CN113354616B (zh) 二芳基-1,2,4-三唑类化合物及其制法和药物用途
CN111417632B (zh) 噻唑-5-甲酸衍生物及其制备方法与应用
TW201831177A (zh) 醯胺衍生物
KR20260032385A (ko) Glp-1 수용체 효능제 활성을 가진 시에노이미다졸 화합물, 이의 제조 방법, 및 이들의 의약 용도
WO2024012543A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
EA049122B1 (ru) Способ лечения связанных с covid-19 состояний